Voya Investment Management LLC Sells 815,679 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Voya Investment Management LLC cut its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 39.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,255,034 shares of the biotechnology company's stock after selling 815,679 shares during the quarter. Voya Investment Management LLC owned about 0.18% of OPKO Health worth $1,845,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Cibc World Markets Corp bought a new position in OPKO Health in the fourth quarter worth approximately $45,000. Zacks Investment Management acquired a new position in shares of OPKO Health during the fourth quarter worth approximately $49,000. Ieq Capital LLC bought a new position in shares of OPKO Health in the 4th quarter worth $52,000. World Investment Advisors LLC acquired a new stake in OPKO Health in the 3rd quarter valued at $61,000. Finally, Catalyst Funds Management Pty Ltd acquired a new position in OPKO Health during the fourth quarter worth $91,000. Institutional investors own 64.63% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. HC Wainwright reissued a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. initiated coverage on OPKO Health in a research report on Friday, April 25th. They issued a "neutral" rating for the company. StockNews.com downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday. Finally, Barrington Research reiterated an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $2.75.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were acquired at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 767,434 shares of company stock valued at $1,238,312 over the last quarter. 49.69% of the stock is owned by company insiders.

OPKO Health Price Performance

OPK stock traded down $0.04 during mid-day trading on Wednesday, hitting $1.25. 4,221,443 shares of the stock were exchanged, compared to its average volume of 3,890,748. The stock has a market capitalization of $987.35 million, a price-to-earnings ratio of -6.55 and a beta of 1.42. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a 12 month low of $1.15 and a 12 month high of $2.04. The business has a fifty day moving average price of $1.59 and a 200 day moving average price of $1.56.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $149.90 million during the quarter, compared to analysts' expectations of $163.13 million. During the same quarter in the prior year, the firm posted ($0.12) EPS. The firm's quarterly revenue was down 13.7% on a year-over-year basis. On average, sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.